Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Continuous data are reported as median (IQR)Enrolled patients N 536 Anthropometric characteristics Age (yrs)62.3 (47.9 to 73.0) 18 to 40 74 (13.8%) 41 to 50 73 (13.6%) 51 to 60 88 (16.4%) 61 to 70 122 (22.8%) 71 to 80 128 (23.9%) > 80 47 (8.8%) n.a. 4 (0.7%)Height (m)1.73 (1.69 to 1.78)Weight (kg)77 (69 to 85)BMI (kg/m2)25.3 (23.2 to 28.1) Source of referral Endocrinologist197 (36.8%)General practitioner229 (42.7%)Other specialists110 (20.5%)Risk factors, comorbidities and therapies associated with osteoporosisAge > 65 years242 (45.4%)BMI < 18 kg/m27 (1.3%)Familial history of osteoporosis134 (27.6%)Parental history of hip fracture44 (9.3%)Smoke166 (31.8%)Alcohol consumption > 3 units/day27 (5.3%)Inconstant physical activity393 (78.6%)Low dietary calcium intake44 (8.8%)FRAX score for hip fracture (%)2.3 (0.9 to 6.2)FRAX score ≥ 3% for hip fracture204/471 (43.3%)FRAX score for major fracture (%)6.5 (3.6 to 12.0)FRAX score ≥ 20% for major fracture43/469 (9.2%)Comorbidities < 2226 (42.2%)Comorbidities ≥ 2310 (57.8%) Vitamin D status ≤ 10 ng/ml31 (5.8%)11 to 20 ng/ml128 (23.9%)21 to 30 ng/ml198 (36.9%)> 30 ng/ml139 (25.9%)Not available40 (7.5%) Management for bone health before bone specialist’s evaluation Neither prior calcium and/or vitamin D supplementation nor drugs181 (33.8%)Prior calcium and/or vitamin D supplementation, no drugs219 (40.8%)Ongoing calcium-vitamin D supplementation, prior anti-osteoporotic medications26 (4.9%)Ongoing drugs plus calcium and/or vitamin D supplementation99 (18.5%)Ongoing drugs without calcium-vitamin D supplementation11 (2.1%)n.a.: not available.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This cohort study documented the real-life clinical management of male outpatients referring for the first time to the Endocrinology Unit of University of Modena and Reggio Emilia for a bone health evaluation.

Source: Methods.

Between May 2007 and December 2021, a total of 536 male patients were enrolled.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Too late, too often: missed opportunities in male bone health: a real-world portrait from a 14-year specialist referral experience

Cohort study · Journal of Endocrinological Investigation · 2025

Original publication title

Too late, too often: missed opportunities in male bone health: a real-world portrait from a 14-year specialist referral experience

Sara De Vincentis; Antonino Russo; Erica Taliani; Anna Ansaloni; Daniela Domenici; Giulia D’Angelo; Veronica Demichelis; Bruno Madeo; Vincenzo Rochira

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Male osteoporosis presents with a high rate of fractures in the real-life clinical practice at a tertiary academic center. The high prevalence of comorbidities associated with bone loss suggests that secondary forms of osteoporosis should be carefully investigated, even in presence of normal BMD. The significant proportion of untreated men: including those with known risk factors or fractures: highlights the urgent need to raise awareness and improve the management of male osteoporosis, especially in primary healthcare.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To characterize, using real-life data, the clinical profile of men undergoing their first bone health evaluation at a tertiary academic center over a 14-year period.

Source: Purpose

Abstract: What methods does the paper describe?

Retrospective, observational, cross-sectional study including adult men referred to our center between 2007 and 2021 for bone health assessment. Fractures, comorbidities, risk factors for bone loss, and pharmacological treatments were collected.

Source: Methods

Abstract: Results

536 men were enrolled (147 under 50, 385 over 50). At least one comorbidity associated with bone loss was found in 49.3% of patients, and 43.8% were receiving medications causing bone mineral density (BMD) reduction: mainly corticosteroids and androgen deprivation therapy. The prevalence of osteoporosis, osteopenia, and low BMD for age was 42.3%, 44.8%, and 48.6%, respectively. Osteoporosis-related fractures were found in 216 patients (40.8%), whose 34 men under 50 (15.7%). Up to 17.5% of men with fractures had normal BMD.

A total of 181 patients (33.8%) had never received calcium/vitamin D supplementation or bone-active therapy; the prevalence of treatment-naïve patients was 20 to 23% even among men with fractures or receiving corticosteroids/androgen-deprivation therapy.

Source: Results

Abstract: Conclusions

Male osteoporosis presents with a high rate of fractures in the real-life clinical practice at a tertiary academic center. The high prevalence of comorbidities associated with bone loss suggests that secondary forms of osteoporosis should be carefully investigated, even in presence of normal BMD. The significant proportion of untreated men: including those with known risk factors or fractures: highlights the urgent need to raise awareness and improve the management of male osteoporosis, especially in primary healthcare.

Source: Conclusions
Authors’ abstract

Purpose

To characterize, using real-life data, the clinical profile of men undergoing their first bone health evaluation at a tertiary academic center over a 14-year period.

Methods

Retrospective, observational, cross-sectional study including adult men referred to our center between 2007 and 2021 for bone health assessment. Fractures, comorbidities, risk factors for bone loss, and pharmacological treatments were collected.

Results

536 men were enrolled (147 under 50, 385 over 50). At least one comorbidity associated with bone loss was found in 49.3% of patients, and 43.8% were receiving medications causing bone mineral density (BMD) reduction: mainly corticosteroids and androgen deprivation therapy. The prevalence of osteoporosis, osteopenia, and low BMD for age was 42.3%, 44.8%, and 48.6%, respectively. Osteoporosis-related fractures were found in 216 patients (40.8%), whose 34 men under 50 (15.7%). Up to 17.5% of men with fractures had normal BMD.

A total of 181 patients (33.8%) had never received calcium/vitamin D supplementation or bone-active therapy; the prevalence of treatment-naïve patients was 20 to 23% even among men with fractures or receiving corticosteroids/androgen-deprivation therapy.

Conclusions

Male osteoporosis presents with a high rate of fractures in the real-life clinical practice at a tertiary academic center. The high prevalence of comorbidities associated with bone loss suggests that secondary forms of osteoporosis should be carefully investigated, even in presence of normal BMD. The significant proportion of untreated men: including those with known risk factors or fractures: highlights the urgent need to raise awareness and improve the management of male osteoporosis, especially in primary healthcare.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-025-02753-8.

Publication and source details

Original title: Too late, too often: missed opportunities in male bone health: a real-world portrait from a 14-year specialist referral experience

Sara De Vincentis; Antonino Russo; Erica Taliani; Anna Ansaloni; Daniela Domenici; Giulia D’Angelo; Veronica Demichelis; Bruno Madeo; Vincenzo Rochira

Journal of Endocrinological Investigation · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Modena e Reggio Emilia

Open access funding provided by Università degli Studi di Modena e Reggio Emilia within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:07:36.973574+00:00

DOI: 10.1007/s40618-025-02753-8 · PMC13017997